Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.

@article{Marchesoni2003RadiographicPI,
  title={Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.},
  author={Antonio Marchesoni and Norma Battafarano and Marco Arreghini and Benedetta Panni and Mauro Battista Gallazzi and Sergio Tosi},
  journal={Rheumatology},
  year={2003},
  volume={42 12},
  pages={
          1545-9
        }
}
OBJECTIVE To determine whether patients with early rheumatoid arthritis (RA) treated with cyclosporin A (CsA) and methotrexate (MTX) in combination for 12 months show a lower rate of radiographic deterioration than those treated with MTX alone. METHODS In this controlled and randomized single-blind trial, 61 consecutive patients with untreated RA of less than 2 yr duration were treated with either CsA + MTX combination therapy (n = 30) or MTX alone (n = 31). The primary end-point was… Expand
Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial
TLDR
In patients with early RA, neither CsA plus MTX combination therapy nor Cs a monotherapy is very effective in inducing clinical remission, and combination therapy is probably better at improving clinical disease activity, and definitely better at slowing radiological progression. Expand
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
TLDR
This study confirms the existence of a “window of opportunity” in early RA, when intensive combination therapy produces sustained benefits on damage and disability and the synergistic effect of two DMARDs is needed to improve quality of life. Expand
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
TLDR
In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy. Expand
Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial
TLDR
Early and strict synovitis suppressive treatment with MTX and intra-articular GC lead to high remission rates and halting of erosive progression at 5 years, parallel those reported for tumour necrosis factor α antagonists. Expand
A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.
TLDR
There is strong evidence in favour of combination treatment for RA but there is still uncertainty about which regimen is preferable, and both combination DMARDs and TNF/MTX are more effective than MTX monotherapy. Expand
Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
TLDR
A moderate level of evidence from the systematic review showed no statistically significant advantage of the MTX combination versus monotherapy, and trials are needed that compare currently used MTX doses and combination therapies. Expand
Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study.
TLDR
Combined treatment with methotrexate and intraarticular glucocorticoid showed excellent disease control and stopped the progression of erosions in patients with early active RA, who had a poor prognosis. Expand
Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate
TLDR
It is concluded there is no evidence that intensive therapy in early rheumatoid arthritis causes unaccep... Expand
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
TLDR
Considering the balance of efficacy and toxicity, the current study provides evidence that MTX + SIN combination therapy is probably one of the choices for treating patients with active rheumatoid arthritis in addition to MTX-+- LEF combination therapy. Expand
Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
TLDR
Treatment with DMARDs, glucocorticoids, biologic agents, and combination agents significantly reduced radiographic progression at 1 year, with a relative effect of 48-84%. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study
TLDR
CsA can delay radiological disease progression and may inhibit joint damage deterioration in early RA patients and early immunointervention in RA patients appears to be crucial for the future development of joint damage. Expand
Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.
TLDR
In poor-prognosis RA patients, "aggressive" combination therapy led to more rapid disease suppression but did not result in significantly better ACR response or remission rates, which suggests that in poor- Prognosis disease, an approach based on identifying patients with poor treatment responses before extra therapy is added ("step-up" approach) may be more appropriate than the use of combination therapy in all patients from the outset. Expand
Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study
TLDR
The clinical improvement previously observed in patients treated with the CSA + MTX combination for 24 weeks was maintained for 24 subsequent weeks, without serious adverse effects, and was also observed in the patients whose treatment was switched from placebo +MTX to CSA+MTX. Expand
Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A.
TLDR
These 12-month results suggest that low-dose CsA decreases the rate of further joint damage in previously involved joints as well as the rates of new joint involvement in previously uninvolved joints, in patients with early active rheumatoid arthritis. Expand
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
TLDR
In a six-month study, patients with severe rheumatoid arthritis and only partial responses to methotrexate had clinically important improvement after combination therapy with cyclosporine and metotrexate. Expand
Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis.
TLDR
Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX, and other approaches may be more appropriate inEarly RA. Expand
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.
TLDR
The aim of this study was to assess the efficacy of adding cyclosporin A (Cs) to the treatment of early RA patients without previous DMARD or steroid treatment who did not respond sufficiently to a high dose of parenteral MTX combined with a moderate dose of glucocorticoids given for 8 weeks. Expand
Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension
TLDR
Three year changes in radiographic damage during cyclosporin and parenteral gold were similar in patients with early, active RA, and normal renal function and raised blood pressure were often seen in the cyclosporain treated patients. Expand
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
TLDR
Combination therapy was better and not more hazardous than single treatment in induction of remission in early rheumatoid arthritis, and the combination strategy as an initial therapy seems to increase the efficacy of the treatment in at least a proportion of patients with early r HEA. Expand
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study.
TLDR
Findings show that a delay in instituting therapy with second-line agents, even a 9 month delay, has significant effects on longterm patient outcome, and provides strong evidence in support of early therapy in RA. Expand
...
1
2
3
4
...